Tag:

BioTime

Latest Headlines

Latest Headlines

BioTime enters academic collaborations to advance its hydrogel for vocal fold scarring

BioTime is entering into a partnership with the University of Wisconsin and Belgium's Louvain University to develop the company's hydrogel-based treatment for vocal fold scarring.

Geron unloads its stem cell coffers to BioTime in stock deal

After more than a year of not-so-secret negotiations, Geron has finally auctioned off its long-stalled embryonic stem cell pipeline, handing it over to a newly created BioTime subsidiary in exchange for shares.

BioTime, Jade extend hydrogel license for human-eye use

BioTime, the Alameda, CA-based maker of a hydrogel technology for drug delivery, signed an exclusive sublicense agreement with Jade Therapeutics to allow the Utah company to use the hydrogel in its own sustained-release treatments for the eye.

Ex-Geron chief spearheads bid to revive mothballed stem cell studies

Back in early 2011 Geron CEO Thomas Okarma was forced to step aside as the biotech prepared to bring in a new CEO to restructure the operations. Now Okarma is back, leading a new regenerative medicine venture set up by BioTime. And he wants his stem cell work back.

LifeMap born to create stem cell database

There's a new database in the works for researchers to view details on the progression of embryonic stem cells to more mature states. LifeMap Sciences, a newly formed subsidiary of Alameda, CA-based

BioTime, CIRM reach deal on embryonic stem cell lines

BioTime, an Alameda, CA-based company specializing in regenerative medicine, will provide five clinical-grade human embryonic stem cell lines to the California Institute for Regenerative Medicine,

BioTime soars on cell aging reversal

Shares of BioTime shot up over 33 percent this morning after investors got a whiff of a newly published scientific paper in which the biotech company says it was able to reverse the aging process in

BioTime shares soar as researchers reverse cell aging

Shares of BioTime shot up more than 33 percent this morning after investors got a whiff of a newly published scientific paper in which the biotech company says it was able to reverse the aging